Child Dies in Chinese Biotech Firm's Gene Editing Trial, Raising Concerns Over Transparency and Oversight China's ambitious plans to become a biotechnology powerhouse have led to a surge in cutting edge cell and gene therapies.
However, this approach has also raised concerns about oversight, safety reporting, and public disclosure.
The recent death of a child with Duchenne muscular dystrophy after receiving a gene editing therapy in a trial conducted by Shanghai based HuidaGene Therapeutics highlights the opaque nature of these trials.